Form 4: Applied Therapeutics Executive Leslie Funtleyder Granted 300,000 RSUs; Prior Holdings Corrected

Applied Therapeutics, Inc. disclosed that Leslie D. Funtleyder, Director, CFO, and Interim CEO, was granted 300,000 Restricted Stock Units and reported a correction to previously overstated beneficial ownership.

Summary

• Leslie D. Funtleyder, Director, Chief Financial Officer, and Interim Chief Executive Officer of Applied Therapeutics, Inc., was granted a total of 300,000 Restricted Stock Units (RSUs).
• On June 9, 2025, 150,000 compensatory RSUs were granted, vesting in equal monthly installments over 24 months starting April 1, 2025.
• On July 1, 2025, an additional 150,000 compensatory RSUs were granted, vesting in equal monthly installments over 24 months starting July 1, 2025.
• All RSUs were granted under the company's 2019 Equity Incentive Plan and represent a contingent right to receive one share of common stock each, subject to continued service.
• The total beneficial holdings of Leslie D. Funtleyder were adjusted to correct an administrative error in prior Form 4 filings that had resulted in an overstatement of total holdings.
• Following the reported transactions, Leslie D. Funtleyder's total beneficial ownership stands at 937,121 shares.

Sentiment

Score: 6

Explanation: The document reports routine executive compensation through RSU grants, which is generally positive for aligning interests. However, the disclosure of an administrative error in prior filings, while corrected, introduces a minor negative aspect regarding data accuracy. Overall, it's a neutral to slightly positive filing due to the incentive alignment.

Positives

• Grant of 300,000 Restricted Stock Units to a key executive, Leslie D. Funtleyder, aligns management incentives with shareholder interests and serves as a retention mechanism.
• The grants are compensatory, indicating ongoing commitment to executive compensation through equity.

Negatives

• An administrative error in prior Form 4 filings led to an overstatement of total beneficial holdings, requiring a correction.

Risks

• Potential for administrative errors in financial reporting, as evidenced by the overstatement of holdings in prior Form 4s.

Future Outlook

The vesting schedules for the granted Restricted Stock Units extend over 24 months from April 1, 2025, and July 1, 2025, respectively, contingent on the reporting person's continued service, indicating a long-term incentive structure.

Management Comments

• Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in equal monthly installments over the twenty-four month period immediately following April 1, 2025, subject to the Reporting Person continuing to provide services through each such date.
• The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the overstatement of the total holdings.
• Consists of compensatory RSUs granted under the Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in equal monthly installments over the twenty-four month period immediately following July 1, 2025, subject to the Reporting Person continuing to provide services through each such date.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the biotechnology or pharmaceutical industry, where equity grants like Restricted Stock Units are commonly used to attract, retain, and incentivize key management personnel, aligning their interests with long-term company performance. The correction of an administrative error highlights the importance of accurate and transparent reporting, a critical aspect across all regulated industries.

Comparison to Industry Standards

• The grant of 300,000 Restricted Stock Units to a key executive like the CFO and Interim CEO is a common practice in the biotech sector for retention and performance incentives.
• While specific comparable companies or projects are not detailed in this filing, such equity grants are standard across companies of similar market capitalization and development stage, such as those seen at smaller to mid-cap biopharmaceutical firms like Mirati Therapeutics or Blueprint Medicines, where executive compensation packages frequently include substantial RSU components tied to multi-year vesting schedules.
• The administrative error correction, while a negative, is not uncommon in the broader context of complex financial reporting across industries, though it underscores the need for robust internal controls.

Management Changes

Stakeholder Impact

• Shareholders: The RSU grants align the interests of a key executive with shareholders, as the value of the RSUs is tied to the company's stock performance. The correction of prior administrative errors improves data accuracy for investors.
• Employees: The grants demonstrate the company's commitment to executive compensation and retention, which can positively influence overall employee morale and perception of the company's stability.

Next Steps

• Continued vesting of 150,000 RSUs in equal monthly installments over 24 months following April 1, 2025.
• Continued vesting of 150,000 RSUs in equal monthly installments over 24 months following July 1, 2025.

Key Dates

Recommendation

Keywords

Applied Therapeutics, APLT, Form 4, SEC filing, Restricted Stock Units, RSUs, Executive Compensation, Insider Trading, Beneficial Ownership, Leslie D. Funtleyder, Chief Financial Officer, Interim Chief Executive Officer, Equity Incentive Plan